English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The first lung transplantation in 1963 brought hope to patients with endstage lung disease. In the two decades that followed, short-term survival remained dismal, primarily because of early surgical complications such as anastomosis dehiscence and early post-transplant allograft rejection. With advances in surgical techniques and new immunosuppression regimens, 1-year survival improved to greater than 90%. Unfortunately, long-term survival still remains low, with only 50% of patients surviving 5–6 years after transplant. Chronic lung allograft dysfunction (CLAD), an umbrella term used to describe recognized phenotypes of chronic lung rejection (1), is a leading contributor to poor long-term survival. With no available therapies for CLAD, current management strategies are focused on early detection and treatment of CLAD risk factors, which include primary graft dysfunction, acute cellular rejection (ACR), antibody-mediated rejection (AMR), and community-acquired respiratory viral infections (1–4). The introduction of genomic, proteomic, and other “omic” approaches have reenergized a new wave of innovative research that promises to improve long-term outcomes via early detection of CLAD and its risk factors. One such innovative project focused on assessing the benefit of early detection and treatment of AMR by means of a noninvasive genomic technology—donorderived cell-free DNA (%ddcfDNA; Figure 1)—and received the 2018 American Thoracic Society (ATS) Building Education to Advance Research (BEAR) Cage Innovation Award.

2018 ATS BEAR Cage Winning Proposal: Cell-Free DNA to Improve Lung Transplant Outcomes